Abstract: A human monoclonal heterosubtypic antibody, MAb 3.1, with its heavy chain encoded by VH3-30, was isolated using phage display with immobilized hemagglutinin (HA) from influenza virus A/Japan/305/1957(H2N2) as the target. Antibody 3.1 potently neutralizes influenza viruses from the H1a clade (i.e., H1, H2, H5, H6) but has little neutralizing activity against the H1b clade. Its crystal structure in complex with HA from a pandemic H1N1 influenza virus, A/South Carolina/1/1918(H1N1), revealed that like other heterosubtypic anti-influenza virus antibodies, MAb 3.1 contacts a hydrophobic groove in the HA stem, primarily us-ing its heavy chain. However, in contrast to the closely related monoclonal antibody (Mab) FI6 that relies heavily on HCDR3 for binding, MAb 3.1 utilizes residues from HCDR1, HCDR3, and framework region 3 (FR3). Interestingly, HCDR1 of MAb 3.1 adopts an alpha-helical conformation and engages in hydrophobic interactions with the HA very similar to those of the de novo in silico-designed and affinity-matured synthetic protein HB36.3. These findings improve our understanding of the molecular requirements for binding to the conserved epitope in the stem of the HA protein and, therefore, aid the development of more universal influenza vaccines targeting these epitopes. IMPORTANCE Influenza viruses rapidly evade preexisting immunity by constantly altering the immunodominant neutralizing antibody epitopes (antigenic drift) or by acquiring new envelope serotypes (antigenic shift). As a consequence, the majority of antibodies elicited by immunization or infection protect only against the immunizing or closely related strains. Here, we describe a novel monoclonal antibody that recognizes the conserved heterosubtypic epitope in the stem of influenza A virus hemagglutinin. This antibody, referred to as MAb 3.1, recognizes its epitope in a manner that resembles recognition of a similar epitope by the de novo in silico-designed and affinity-matured synthetic protein HB36.3. Thus, besides providing novel insights into the molecular interactions between heterosubtypic antibodies and influenza virus hemagglutinin, MAb 3.1 demonstrates that de novo in silico-designed and affinity-matured synthetic proteins can foretell naturally selected antibody binding. This knowledge will aid development of a pan-influenza virus vaccine. 
by V H 3--30, was isolated using phage display with immobilized hemagglutinin from 23 A/Japan/305/1957(H2N2) as the target. Antibody 3.1 potently neutralizes influenza 24 viruses from the H1a clade (i.e. H1, H2, H5, H6), but has little neutralizing activity against 25 the H1b clade. Its crystal structure in complex with HA from a pandemic H1N1 influenza 26 virus A/South Carolina/1/18(H1N1) revealed that, like other heterosubtypic anti--27 influenza antibodies, mAb3.1 contacts a hydrophobic groove in the HA stem, primarily 28 using its heavy chain. However, in contrast to the closely related mAb FI6 that relies 29 heavily on HCDR3 for binding, mAb 3.1 utilizes residues from HCDR1, HCDR3 and FR3. 30 Interestingly, HCDR1 of mAb 3.1 adopts anα--helical conformation and engages in very 31 similar hydrophobic interactions with the HA as the de novo in silico designed and 32 affinity matured synthetic protein HB36.3. These findings improved our understanding 33 of the molecular requirements for binding to the conserved epitope in the stem of the 34 HA protein and, therefore, aid the development of more universal influenza vaccines 35 targeting these epitopes. 36
Introduction

51
Hemagglutinin (HA), the surface protein responsible for receptor attachment and entry 52 of influenza A viruses, has currently been classified into 18 distinct subtypes (H1--H18) 53 that can be combined into two separate phylogenetic groups (1, 2). HA is initially 54 synthesized as an inactive form (HA0) that is processed to its fusion--active form by 55 cleavage into covalently linked HA1 and HA2 subunits. These assemble as trimers of 56 heterodimers consisting of an apical globular head from the HA1 subunit that is 57 responsible for mediated receptor binding, and a stem region containing the fusion 58 machinery, which is constructed by HA2 and the N and C--termini of HA1. Antibodies 59 elicited during infection and immunization bind to highly antigenic sites surrounding the 60 receptor binding site on HA1, and typically interfere with receptor binding (3--6). As 61 these antigenic sites are also subject to the highest antigenic variation, most antibodies 62 Recombinant HA, stabilized by a His--tagged trimerization domain, was expressed into 170 the supernatant of baculovirus--infected SF9 insect cells as previously described (37) . 171
After 4 days, supernatant was harvested and soluble protein purified by metal affinity 172 chromatography (Ni--NTA columns, GE Healthcare). Purified HA was proteolytically 173 processed into its HA1 and HA2 subunits using 10U of TPCK--treated trypsin (bovine 174 pancrease, Sigma Aldrich) per 1 μg of HA for 1h at RT. Following digestion, trypsin was 175 removed by size exclusion chromatography using a 200ml Superdex® S200 gel filtration 176 column (GE Healthcare). For further experiments, only the fraction corresponding to the 177 HA trimer was used. 178
Expression and purification of recombinant Fab or IgG1 molecules 179
For purification of Fab 3.1, the protocol by Barbas et al. was followed (36). Briefly, the 180 phagemid containing the 3.1 sequences was transformed into chemically competent 181 TOP 10 E. coli cells (Invitrogen). A single colony from the transformation plate was 182 inoculated into LB supplemented with carbenicilin (50 μg/ml), and grown under 183 agitation (200 rpm) at 37⁰C over night. This pre--culture was then diluted 1:100 in SB 184 supplemented with carbenicilin (50 μg/ml) and 20 mM MgCl 2 , and was grown under 185 agitation (250 rpm) at 37⁰C for 24h. Bacterial cells were harvested by centrifugation and 186 disrupted using a sonicator (Branson Sonifier 250). Lysate was cleared by centrifugation 187 (>13500rpm for 60min) and filtration at 0.2 µm, and Fab fragments isolated by affinity 188 chromatography using protein G slurry (GE healthcare). Bound Fab was eluted from the 189 column using 0.1 M glycine pH 3, and stored in PBS at 4°C after buffer exchange. 190 For expression of soluble IgG 3.1, FI6 and the FI6--3.1 hybrid, the variable regions of 191 heavy and light chains were cloned into the corresponding pIg--Abvec plasmids (38) . from A/Duck/Alberta/60/76(H12N5)) was detected by ELISA. To this end, half--area, high 202 binding capacity plates (Costar) were coated with 25 μl/well of 2 μg/ml HA in PBS at 4 ⁰C 203 over night. Plates were then blocked with 2% milk in PBS. IgG were titrated in 0.2% milk 204 PBS, transferred to the blocked ELISA plates, and allowed to bind for 1 h. After washing 205 with TBST (0.1% Tween), bound Ig was detected using a goat anti--human kappa--HRP 206 secondary antibody (Southern Biotech) and developed using TMB as a substrate. As a 207 negative control, HIV gp120--specific and 293T--cell expressed mAb b12 antibody was 208
used. 209
Neutralization of Influenza A viruses 210
Titrated amounts of IgG 3.1, or IgG1--b12 as negative control, were mixed in triplicate 211 with a fixed amount of Influenza A virus corresponding to MOI 2--3 (~ 10 5 pfu) in DMEM 212 medium supplemented with 0.2% BSA, 20 mM HEPES, 50U/ml penicillin and 50µg/ml 213 streptomycin (DMEM/BSA). After incubation at 37⁰C/5%CO 2 for 2h, the mAb--virus 214 mixture was transferred to PBS--washed, sub--confluent MDCK cells seeded into 96--well 215 tissue culture plates the day before (1 to 2x10 4 cells/ well, TPP), and incubated at 216 37⁰C/5% CO 2 for 1h to allow infection. Residual virus and antibody was aspirated, cells 217 washed with PBS, and DMEM/BSA was added. Following incubation at 37°C/5% CO 2 for 218 4.5 to 7h (depending on the growth kinetics of the virus isolate), cells were fixed with 219 methanol, washed and stained with a 3µg/ml FITC--labeled antibody to influenza NP 220 (ATCC HB--65™) in PBS containing 1% BSA at 4°C overnight. After washing, the FITC--221 labeled antibody, cells were stained with DAPI to control for cell density or cell loss. The 222 corresponding fluorescence was then measured in each well at 16 (FITC) and 9 (DAPI) 223 distinct locations in a Perkin Elmer plate reader. For each well, the average for all 224 individual fluorescence measuring points was calculated and used for further analysis. 225
EC 50 values were determined in Prism 5 (GraphPad Software) using iterative computing 226 of the best fitting Hill equation. 227
Infectivity reduction assay 228 40µl of DMEM/BSA containing 60µg/ml of the antibody of interest were mixed with 80µl 229 of untitrated virus supernatant and incubated for 90min at 37°C/CO 2 . As a control, the12 same amount of virus was mock incubated with DMEM/BSA without antibody. Following 231 incubation for 90min at 37°/5%CO 2 , non--neutralized infectivity was determined by serial 232 diluting the virus/antibody mixture 1 in 2, and infection of 2--4x10 4 MDCK cells with this 233 dilution series. Infection was allowed to proceed 5--6 hours before cells were fixed and 234 stained with a FITC--labeled antibody to NP, as described above. 235
Structural homology search 236
To identify the closest structural homologs of mAb 3.1, the coordinates for the 3.1 237 antibody heavy and light chain were extracted from the structure of the complex and 238 submitted to the PDBe (http://www.ebi.ac.uk/msd--srv/ssm/ssmstart.html) or DALI 239 (http://ekhidna.biocenter.helsinki.fi/dali_server/) structural homology search engines as 240 a pdb file. 241
K D values were determined by bio--layer interferometry (BLI) using an Octet Red 243 instrument (ForteBio, Inc.) as described in (10). Biotinylated HAs were used for these 244 measurements. HAs at ~10--50 µg/mL in 1X kinetics buffer (1X PBS, pH 7.4, 0.01% BSA, 245 and 0.002% Tween 20) were loaded onto streptavidin--coated biosensors and incubated 246 with varying concentrations of mAb3.1 Fab. If no initial binding was observed using the 247 above conditions, mAb3.1 concentrations up to 1µM were used to detect whether any 248 changes could be observed in the binding curves. Crystallization and structure determination of mAb 3.1 Fab 278
The methods used to determine the mAb 3.1 Fab structure were very similar to those 279 described above. Briefly, Fab 3.1 at 15mg/ml in 10mM Tris, pH 8.0 and 50 mM NaCl was 280 subjected, after gel filtration, to robotic crystallization trials using the Rigaku 281
Crystalmation robotic system at the JCSG. Several hits were obtained. The crystals used 282 for data collection were grown by the sitting drop vapor diffusion method with a 283 reservoir solution (1 ml) containing 0.2 M calcium acetate, 10% PEG 8000 and 100 mM 284 Tris pH 7.0. The resulting crystals were cryoprotected by soaking in well solution 285 supplemented with 35% ethylene glycol, then flash cooled and stored in liquid nitrogen 286 until data collection. 287
The Fab 3.1 dataset was collected to 2.7 Å resolution at APS GM/CA--CAT 23ID--B 288 beamline. Data collection and refinement statistics are summarized in Suppl. Table 4 . 289
The structure was solved using the same strategies as described above for the Fab 3.1--290 Sc1918/H1 complex. 291
Structural analysis 292
Hydrogen bonds and van der Waals' contacts between Fab 3.1 and Sc1918/H1 HA were 293 calculated using HBPLUS and CONTACSYM, respectively (42, 43) . Surface area buried 294 upon Fab binding to the HA was calculated with MS (44). MacPyMol (DeLano Scientific) 295 was used to render structure figures and for general manipulations. Kabat numbering 296 was applied to the coordinates using the Abnum server (45). The final coordinates were 297 validated using the JCSG quality control server (v2.7), which includes MolProbity (46). 298
Results
299
Isolation and characterization of monoclonal antibody 3.1 300
Using RNA isolated from mature B cells of a healthy donor, a Fab phage display library 301 was prepared and used for panning against trimeric baculovirus--expressed HA from 302 A/Japan/305/1957(H2N2) (6) that was reversibly immobilized on magnetic beads. The 303 H2 subtype was chosen for two reasons: first, antibody epitope mapping suggested that 304 there is an antigenic site in the stem of this subtype protein that is not present in other 305 human HA subtypes. (5, 6). Second, the donor of the B cells used for the preparation of 306 the phage library was born in 1976 and should therefore be immunologically naïve to 307 the H2 subtype that ceased circulating in humans in 1967. Consequently, H2--binding 308 antibodies isolated from this donor are by definition bona fide natural heterosubtypic or 309 cross--reactive antibodies that arose from novel heavy--light--chain combinations 310 generated during the phage display library preparation. 311
After four rounds of panning, 13 clones were selected for further characterization. Nine 312 out of thirteen clones possessed the same heavy chain paired to different light chains 313 with the remaining four only differing in a maximum of four nucleotides from the 314 consensus sequence. The light chain repertoire was more diverse and included 7 distinct 315 kappa and 3 distinct lambda light chains (Supp. Table 1 ). While the common heavy chain 316 of all clones shared the very same VDJ--gene segment usage as mAb FI6 (IGHV3--30, 317 IGHD3--9, IGHJ4*01;7), none of the light chains isolated in this experiment displayed the 318 same IGKV4--1 x IGKJ1 genotype of the FI6 light chain (Suppl. Table 1 ). Since at that time 319 the mutations that enable FI6 to recognize also HA subtypes from phylogenetic group 2 320
were not known, we randomly selected a representative clone based on phage--ELISA 321 data using H2 as coating antigen. This clone, referred to as mAb 3.1, expressed the 322 common heavy chain paired to an IGκV1--12 x IGκJ4*01 light chain. Its light chain did not 323 display somatic hypermutation, and only nucleotide replacements in FR1 that caused 324 amino acid residues at positions 1 and 2 (IMGT numbering) to differ from the reference 325 alleles deposited at IMGT were found. However, these mutations are most likely an 326 artifact arising from serial PCR amplification required for the preparation of a phage 327 display library (36). 328
Specificity of mAb 3.1 329
In enzyme--linked immunosorbent assays (ELISA), mAb 3. A/shearwater/W. Australia/2576/79(H15N9). Thus, mAb 3.1 bound HA proteins from 347 phylogenetic group 1 but did not bind HA proteins belonging to phylogenetic group 2 348 (Supp. Table 2) . 349
The antiviral activity of mAb 3.1 against at least one representative isolate from 350 subtypes H1 through H15 was tested. In hemagglutination inhibition assays, no 351 inhibition of A/Puerto Rico/8/34(H1N1) was found indicating that mAb 3.1 does not 352 interfere with receptor binding (data not shown). Since pseudotyped influenza viruses 353 were described to be more easily neutralized than live virus (31), all neutralization 354 assays were performed with viable influenza viruses. To this end, we established a 355 robust fluorescence--based neutralization assay that employed 10 5 infectious units per 356
well, corresponding to a multiplicity of infection of 2 to 3. Using this assay, mAb 3.1 357 neutralized viruses of the H1, H2, H5, H6 subtypes at half--maximal inhibitory 358 concentrations in the µg/ml range (Figure 1) . Thus, like most V H 1--69--encoded and the 359 germline--reverted variants of FI6, mAb 3.1 was only able to neutralize isolates from 360 phylogenetic group 1. However, within phylogenetic group 1, it did not neutralize 361
isolates from the H1b clade that includes the H11, H13, and H16 subtypes, and it 362 displayed very low antiviral activity against isolates from the H9 clade (i.e. H8, H9, H12) 363 at concentrations over 20µg, if at all. 364
The main differences in the stem epitope between the H1b and the remaining clades are 365 a glycosylation site at position 291 of HA1, and the lack of a proline at position 293. 366
These may interfere with interaction of HA1 with FR3 residues of mAb 3.1. However, 367 since the only exception with this respect, subtype H6, is well recognized by mAb 3.1, 368 these differences alone are unlikely to be the sole reason for the different recognition 369 by mAb3. 
Phe99
C179 and Phe100D FI6 ) into the hydrophobic groove ( Figure 4C ). As in previously 413 described antibodies (CR62621, F10, C179) or designed proteins (HB36 and F--HB80.4) 414 that are specific to group 1 influenza A viruses, mAb 3.1 make a similar interaction with 415
Trp21 where Phe100 at the tip of HCDR3 is in a remarkably similar position and 416 orientation to the aromatics in the other antibodies and designed HA binding proteins 417 ( Figure 4A ) (21, 23, 26, 31, 47, 48) . In contrast to most other heterosubtypic antibodies where the light chain was described 438 not to be essential for binding, FI6 possesses two residues (Phe27d and Arg93) in its 439 light chain whose reversion to germline--encoded serines drastically reduced the ability 440 to bind to HA proteins of phylogenetic group 2 HA, even when introduced individually 441 (23). However, when the FI6 light chain was paired with the heavy chain of 3.1, the 442 22 hybrid antibody displayed the binding and neutralization profile of mAb 3.1, in that it 443 failed to bind to recombinant H3, H7, and H12 and was not able to neutralize viruses 444 belonging to phylogenetic group 2 (data not shown). These results indicate that the 445 beneficial impact of these light--chain residues is specific to FI6. 446
Discussion
447
We isolated a V H 3--30 encoded heterosubtypic monoclonal antibody that can neutralize 448 viruses from the H1a clade very well with low neutralizing activity also against the H9 449 subtype. For its isolation, a novel panning strategy was performed that took advantage 450 of three rational designs. First, by using an HA subtype (H2) to which the donor is naïve 451 as the selecting antigen, all antibodies isolated are bona--fide cross--reactive. Second by 452 tethering HA trimers in an upside--down orientation to beads, the apical strain--specific 453 epitopes were occluded, while the conserved stem--specific epitopes became 454 prominently exposed. Third, using monoclonal antibodies for classical epitope mapping, 455 the H2 subtype was found to have an additional antigenic site 'II--A' in the stem of the 456 HA protein that has not been described for other subtypes (5, 22). Also, the first known 457 monoclonal heterosubtypic antibody C179 was isolated from mice immunized with H2 458 (31). We therefore assumed that H2 may be a particular good subtype for the isolation 459 of stem--specific antibodies. Indeed, the panning readily produced numerous 460 heterosubtypic antibodies confirming that the strategy works. However, as we have 461 been able to isolate much broader heterosubtypic antibodies by panning against a 462 different inverted HA subtype, we do not believe that H2 is exceptionally well--suited for 463 this purpose. 464
As with all phage display experiments, it cannot be conclusively deduced that antibodies 465 isolated using this strategy are in the same heavy--light chain composition as in the 466 natural repertoire of the donor. However, as stem--specific, heterosubtypic antibodies 467 primarily contact their epitope with residues of the heavy chain, especially for the V H 1--468 69 antibodies, we believe that, in this case, this issue is of minor impact. there is no addition of N1 nucleotides, but the N2 region contains 17 nucleotides (5'--486 tcataaggggcattatg--3') encoding for 7 aa (FIRIGIM), two of which (F100, R100B) 487 contribute to binding. In the case of FI6, the N--nucleotide additions are even more 488 extensive with a total of 32 non--templated nucleotides, 22 nt of which are N1 (5'--c tcc 489 caa ctg cga tca ctc ctc--3') and 10 are N2 (5'--cc cag gga tat--3') nucleotides that also 490 contain key residues for heterosubtypic binding (L98, R99). Both antibodies use the D3--9 491 segment that provides these antibodies with two essential hydrophobic residues that 492 insert into the HA hydrophobic groove. Thus, the V H 3--30 germline gene appears to 493 provide good framework for heterosubtypic antibodies as it provides an HCDR1 that can 494 be used to contact the apical region of the conserved stem epitope, in particular if 495 joined to D3--9, or other D regions capable of providing additional hydrophobic residues. 496
Like most other hmAbs, mAb 3.1 can protect mice against a lethal challenge with, in this 497 case, A/Puerto Rico/8/34(H1N1) virus. However, from our data, we cannot conclude 498 whether this protection is directly mediated by its neutralizing activity, or whether other 499 effector mechanisms such as complement activation or Fc--receptor mediated 500 cytotoxicity are of importance. As it has been shown recently that Fc--γ receptor binding 501 is of importance for protection of mice by HA stem--specific antibodies, we assume that 502 the mAb 3.1 protection at least partially relies on antibody--mediated cellular 503 cytotoxicity (49) 504 So far, the antigenic particularity of the H1b clade has been underappreciated. Even the 505 broadest antibody described so far, CR9114 did not neutralize an H11 isolate despite 506 25 good binding to recombinant H13 and H16 HA proteins in ELISA (25). As depicted in 507 Figure  2 , the C--terminal region of HA1 of the H11, H13 and H16 subtypes differs from 508 the other members of phylogenetic group 1 (except H6) by the presence of a N--linked 509 glycosylation site at position 291 and the lack of a proline at position 293. The proximity 510 of these residues to contacting FR3--residues of the antibody may affect binding of 511 heterosubtypic antibodies. We also showed that removal of the glycosylation site by the 512 introduction of a proline at position 293 made H11 more susceptible to neutralization by 513 mAb 3.1. However, when the reciprocal mutations were introduced into H1, no effect 514 was seen, indicating that, depending on the subtype, these mutations alone are not 515 sufficient to affect the neutralization potency of heterosubtypic antibodies. 516
However, further studies will be required to determine the general importance and 517 impact of these two residues on broad reactivity of antibodies. 35  36  37  38  39  40  41  42  43  44  45  46 47 48 285  286  287  288  289  290  291  292  293  294  295  296  297 298 
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